Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
Ardelyx (ARDX) has scheduled a conference call for Thursday, February 20, 2025, at 8:00 a.m. Eastern Time to discuss its full year and fourth quarter 2024 financial results and provide a business update. Participants can join via phone by dialing (877) 346-6112 (domestic) or (848) 280-6350 (international). The call will also be webcast live on the company's website under the Investors section, with a replay available for 30 days following the call.
Ardelyx (ARDX) ha programmato una conference call per giovedì 20 febbraio 2025, alle 8:00 ora orientale, per discutere i risultati finanziari dell'anno completo e del quarto trimestre 2024 e fornire un aggiornamento aziendale. I partecipanti possono unirsi per telefono componendo il numero (877) 346-6112 (nazionale) o (848) 280-6350 (internazionale). La chiamata sarà anche trasmessa in diretta sul sito web dell'azienda nella sezione Investitori, con una registrazione disponibile per 30 giorni dopo la chiamata.
Ardelyx (ARDX) ha programado una conferencia telefónica para el jueves 20 de febrero de 2025, a las 8:00 a.m. hora del Este, para discutir sus resultados financieros del año completo y del cuarto trimestre de 2024 y proporcionar una actualización del negocio. Los participantes pueden unirse por teléfono llamando al (877) 346-6112 (nacional) o al (848) 280-6350 (internacional). La llamada también se transmitirá en vivo en el sitio web de la empresa en la sección de Inversores, con una repetición disponible durante 30 días después de la llamada.
Ardelyx (ARDX)는 2025년 2월 20일 목요일 오전 8시(동부 표준시)에 2024년 전체 연도 및 4분기 재무 결과를 논의하고 비즈니스 업데이트를 제공하는 전화 회의를 예정하고 있습니다. 참가자는 (877) 346-6112(국내) 또는 (848) 280-6350(국제)로 전화를 걸어 참여할 수 있습니다. 이 통화는 또한 투자자 섹션의 회사 웹사이트에서 생중계되며, 통화 후 30일 동안 재생이 가능합니다.
Ardelyx (ARDX) a prévu une conférence téléphonique pour le jeudi 20 février 2025, à 8h00 heure de l'Est, pour discuter de ses résultats financiers de l'année complète et du quatrième trimestre 2024 et fournir une mise à jour sur l'entreprise. Les participants peuvent rejoindre par téléphone en composant le (877) 346-6112 (domestique) ou le (848) 280-6350 (international). L'appel sera également diffusé en direct sur le site web de l'entreprise dans la section Investisseurs, avec un enregistrement disponible pendant 30 jours après l'appel.
Ardelyx (ARDX) hat eine Telefonkonferenz für Donnerstag, den 20. Februar 2025, um 8:00 Uhr Eastern Time angesetzt, um die Jahres- und vierten Quartalsfinanzergebnisse 2024 zu erörtern und ein Unternehmensupdate zu geben. Teilnehmer können sich telefonisch unter (877) 346-6112 (inland) oder (848) 280-6350 (international) einwählen. Der Anruf wird auch live auf der Webseite des Unternehmens im Bereich Investoren übertragen, mit einer Aufzeichnung, die 30 Tage nach dem Anruf verfügbar ist.
- None.
- None.
Conference call scheduled for 8:00 a.m. Eastern Time
WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 20, 2025, at 8:00 a.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2024.
To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.
About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
FAQ
When will Ardelyx (ARDX) report Q4 and full-year 2024 earnings?
How can investors join the ARDX Q4 2024 earnings call?
How long will the ARDX Q4 2024 earnings call webcast be available for replay?
Where can I access the webcast for ARDX's Q4 2024 earnings call?
